• The scientists, public advocacy groups, and analysts offer contrasting views as FDA is set to decide on aducanumab, the experimental therapy co-developed by Biogen (NASDAQ:BIIB) and Japanese pharmaceutical company Eisai (OTCPK:ESALF) against Alzheimer’s disease.
• The marketing application for aducanumab was backed by data from two late-stage trials named EMERGE and ENGAGE.
• Noting the inadequacy of EMERGE study to prove its efficacy, an expert panel from the FDA previously declined to endorse the therapy….

Click here to view the original article.